Together, these results indicate that loss of PRLR expression in luminal/HR+ MCF-7 breast cancer cells results in their dedifferentiation to a basal-mesenchymal-like phenotype and further reduce their sensitivity to anti-hormonal therapy. Here, PRLR is linked to breast carcinoma.